While conducting the study, the researchers tracked data from more than 10,000 patients who presented with type 2 diabetes, ...

A newly approved drug for type 2 diabetes and kidney disease, sotagliflozin, has shown remarkable benefits in reducing the ...

Sotagliflozin, recently approved by the FDA for treating type 2 diabetes and kidney disease in patients with cardiovascular ...

The prevalence of diabetes is increasing faster in some low-income countries than elsewhere in the world, generating concerns ...

An FDA-approved medication already used to treat people who have type 2 diabetes and chronic kidney disease may also help ...

Treating older people with diabetes is challenging due to multiple medical comorbidities that might interfere with patients' ...

Sotagliflozin, a drug recently approved by the Food and Drug Administration to treat type 2 diabetes and kidney disease with ...

The results showed that people who took sotagliflozin had a 23% lower risk of heart attacks, strokes, and death from ...

A recent study from the FINEARTS-HF trial revealed that finerenone, which is an oral mineralocorticoid receptor antagonist, ...

The dual SGLT1/2 inhibitor sotagliflozin (Inpefa) reduced the risk for myocardial infarction (MI) and stroke in high-risk ...

Sotagliflozin, a drug recently approved by the Food and Drug Administration to treat type 2 diabetes and kidney disease with additional cardiovascular risk factors, can significantly reduce heart ...

Lexicon (LXRX) announced The Lancet Diabetes & Endocrinology has published a research paper analyzing the ability of sotagliflozin, a dual ...